Consistently, the levels of interleukin 6 (IL-6) are increased in severe and critically ill COVID-19 patients, which is thus being considered as the prognostic and predictive disease biomarker along with the numbers of neutrophil/lymphocytes (Liu et al., 2020; Santa Cruz, 2021). This evidence concerns the gene IL6 and COVID-19.